However, recent studies have proven otherwise as intracellular insulin paucity (characteristic of both type 1 and 2) is what leads to low levels of CYP7B1 and the accumulation of toxic cholesterol metabolites, explaining the existence of MASLD progression with both types of diabetes. This evidence concerns the gene CYP7B1 and metabolic dysfunction-associated steatotic liver disease.